Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

[This corrects the article DOI: 10.1371/journal.pone.0164455.].

Saved in:
Bibliographic Details
Published inPloS one Vol. 12; no. 2; p. e0172184
Main Authors Troya, Jesús, Ryan, Pablo, Ribera, Esteban, Podzamczer, Daniel, Hontañón, Victor, Terrón, Jose Alberto, Boix, Vicente, Moreno, Santiago, Barrufet, Pilar, Castaño, Manuel, Carrero, Ana, Galindo, María José, Suárez-Lozano, Ignacio, Knobel, Hernando, Raffo, Miguel, Solís, Javier, Yllescas, María, Esteban, Herminia, González-García, Juan, Berenguer, Juan, Imaz, Arkaitz
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 09.02.2017
Public Library of Science (PLoS)
Subjects
Abacavir
Lamivudine
Online AccessGet full text

Cover

More Information
Summary:[This corrects the article DOI: 10.1371/journal.pone.0164455.].
Bibliography:correction
SourceType-Other Sources-1
content type line 63
ObjectType-Correction/Retraction-1
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0172184